Prosecution Insights
Last updated: April 19, 2026
Application No. 18/279,903

PROCESS FOR PREPARING A MELAMINE CONDENSATION PRODUCT

Non-Final OA §102§103§112
Filed
Sep 01, 2023
Examiner
AULAKH, CHARANJIT
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
BASF Corporation
OA Round
1 (Non-Final)
81%
Grant Probability
Favorable
1-2
OA Rounds
2y 3m
To Grant
65%
With Interview

Examiner Intelligence

Grants 81% — above average
81%
Career Allow Rate
1407 granted / 1741 resolved
+20.8% vs TC avg
Minimal -16% lift
Without
With
+-16.0%
Interview Lift
resolved cases with interview
Typical timeline
2y 3m
Avg Prosecution
54 currently pending
Career history
1795
Total Applications
across all art units

Statute-Specific Performance

§101
1.9%
-38.1% vs TC avg
§103
15.2%
-24.8% vs TC avg
§102
21.0%
-19.0% vs TC avg
§112
42.6%
+2.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1741 resolved cases

Office Action

§102 §103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . According to paper filed on Feb. 11, 2026, the applicants elected group I and furthermore, elected species II through X for further prosecution. Since the applicant’s did not specify the specific structure of elected species, a telephone call was made to applicant’s attorney, Ms. Claudia Schultze on Feb. 27, 2026. During telephone call with Ms. Claudia Schultze on Feb. 27, 2026, the attorney elected compound of formula (I) disclosed on page 2 of specification as specific species for further prosecution. Claims 16-30 are pending in the application. Claim 28 is withdrawn from further consideration as being directed to non-elected subject matter. Claim Rejections - 35 USC § 112 6. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 16, 18-26 and 29-30 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. In independent claim 16, the name or structure of melamine condensation product being prepared, is not defined. Claims 29 and 30 are directed to use of product. These claims are vague and indefinite since the surface or material on which these products are being applied as well as the steps of applying these products are missing in the claims. Claim Rejections - 35 USC § 102 (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 26 and 27 are rejected under 35 U.S.C. 102(a) (1) as being clearly anticipated by Jurgens (J. Am. Chem. Soc., cited on applicant’s form 1449). Jurgens discloses melamine and its use for preparing condensation products. The Compound 4e (melem) disclosed in scheme 4 on page 10290 by Jurgens clearly anticipates the instant claims. It is of note that the instant claims are directed to product by process and therefore, process is irrelevant. Claim 29 is rejected under 35 U.S.C. 102(a) (1) as being anticipated by Heinen (U.S. Patent 6,646,030 B2). Heinen discloses flame retarded compositions. The flame retarded composition comprising melem (see claim 1) anticipates the instant claim when flame retardant is melem. Claim 30 is rejected under 35 U.S.C. 102(a) (1) as being anticipated by Tokunaga (JP 59031861 A, see English translation). Tokunaga discloses use of melamine and its condensation products to regenerate efficiently a salt bath for nitriding a metallic material. The use of melem (a melamine condensation product) to regenerate efficiently a salt bath for nitriding a metallic material disclosed by Tokunaga anticipates the instant claim. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. 13. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. 14. Claims 16-18, 20-21 and 23-25 are rejected under 35 U.S.C. 103 as being unpatentable over De Keuzer (WO 96/16948, cited on applicant’s form 1449) in view of Jurgens (J.Am. Chem. Soc., cited on applicant’s form 1449). DeKeuger discloses a process for preparing melamine condensation products. On page 2 (see lines 3-16), De Keuger discloses a process for producing melamine condensation product (melam) by reacting melamine with zinc and hydrochloric acid. Since the reaction equilibrium shifts to the melam product, at a certain reaction time, a raw product comprising a melamine condensation product and an inorganic residue is formed. De Keuger meets all the limitations of instant claims except that the condensation product is melam instead of melem, does not teach a process for preparing melamine and furthermore, does not mention content of inorganic catalytic residue (at most 2 wt %). However, DeKeuger does teach that melamine condensation products include melem and melam (see page 1, lines 20-21) while Jurgens discloses a process for preparing melamine (see scheme 3 on page 10290). Therefore, it would have been obvious to one skilled in the art to prepare melem as a melamine condensation product by modifying the process of Dekeuger with reasonable expectation of success unless applicants provide unexpected results of superior yield etc. of the present process over the process of DeKeuger by presence of at most 2 wt % content of inorganic catalytic residue. 15. Claims 16-17, 20-23 and 25 are rejected under 35 U.S.C. 103 as being unpatentable over Zheng (J. of Mater. Chem. C, cited on applicant’s form 1449) in view of Jurgens (J.Am. Chem. Soc., cited on applicant’s form 1449). Zheng discloses a process for preparing melamine condensation product. The process for preparing melamine condensation product (melem) by reacting raw material with niric acid disclosed on page 10747 (see experimental section 2.1) by Zheng meets all the limitations of instant claims except that it does not teach a process for preparing melamine and furthermore, does not mention content of inorganic catalytic residue (at most 2 wt %). However, Jurgens discloses a process for preparing melamine (see scheme 3 on page 10290). Therefore, it would have been obvious to one skilled in the art to prepare melem as a melamine condensation product with reasonable expectation of success unless applicants provide unexpected results of superior yield etc. of the present process over the process of Zheng by presence of at most 2 wt % content of inorganic catalytic residue. 16. Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHARANJIT AULAKH whose telephone number is (571)272-0678. The examiner can normally be reached Monday-Friday 7:00-3:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Clinton A Brooks can be reached at 571-270-7682. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CHARANJIT AULAKH/ Primary Examiner, Art Unit 1621
Read full office action

Prosecution Timeline

Sep 01, 2023
Application Filed
Feb 27, 2026
Examiner Interview (Telephonic)
Mar 08, 2026
Non-Final Rejection — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594251
BENZALKONIUM CHLORIDE FORUSE IN TREATING CONJUNCTIVITIS AND/OR COVID-19
2y 5m to grant Granted Apr 07, 2026
Patent 12583829
SALT OF BENZOTHIAZOLE COMPOUND, AND CRYSTAL FORM AND USE THEREOF
2y 5m to grant Granted Mar 24, 2026
Patent 12581852
COMPOUND, LUMINESCENT MATERIAL, DELAYED FLUORESCENT MATERIAL, AND ORGANIC OPTICAL DEVICE
2y 5m to grant Granted Mar 17, 2026
Patent 12569479
BUPROPION AS A MODULATOR OF DRUG ACTIVITY
2y 5m to grant Granted Mar 10, 2026
Patent 12564586
KAPPA OPIOD RECEPTOR ANTAGONISTS FOR TREATING PAIN-RELATED SLEEP DISORDERS
2y 5m to grant Granted Mar 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
81%
Grant Probability
65%
With Interview (-16.0%)
2y 3m
Median Time to Grant
Low
PTA Risk
Based on 1741 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month